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Autosomal-Dominant Multiple Pterygium Syndrome
Is Caused by Mutations in MYH3
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Multiple pterygium syndrome (MPS) is a phenotypically and genetically heterogeneous group of rare Mendelian conditions character-
ized bymultiple pterygia, scoliosis, and congenital contractures of the limbs.MPS typically segregates as an autosomal-recessive disorder,
but rare instances of autosomal-dominant transmission have been reported.Whereas several mutations causing recessiveMPS have been
identified, the genetic basis of dominant MPS remains unknown. We identified four families affected by dominantly transmitted MPS
characterized by pterygia, camptodactyly of the hands, vertebral fusions, and scoliosis. Exome sequencing identified predicted protein-
altering mutations in embryonic myosin heavy chain (MYH3) in three families.MYH3mutations underlie distal arthrogryposis types 1,
2A, and 2B, but all mutations reported to date occur in the head and neck domains. In contrast, two of themutations found to causeMPS
in this study occurred in the tail domain. The phenotypic overlap among persons withMPS, coupledwith physical findings distinct from
other conditions caused by mutations inMYH3, suggests that the developmental mechanism underlying MPS differs from that of other
conditions and/or that certain functions of embryonic myosin might be perturbed by disruption of specific residues and/or domains.
Moreover, the vertebral fusions in persons with MPS, coupled with evidence of MYH3 expression in bone, suggest that embryonic
myosin plays a role in skeletal development.Multiple pterygium syndrome (MPS) is a phenotypically
and genetically heterogeneous group of rare Mendelian
conditions characterized by multiple pterygia, scoliosis
and congenital contractures of the limbs. Most often,
MPS occurs as a simplex case, and of reported multiplex
families, the majority consist of multiple affected siblings
born to unaffected parents, consistent with inheritance
in an autosomal-recessive pattern.1 In very rare instances,
MPS has been transmitted from an affected parent to an
affected child, indicative of autosomal-dominant transmis-
sion.2–5 In 1996, we revised the classification of distal
arthrogryposis (DA) syndromes and categorized several
additional conditions,6 including autosomal-dominant
MPS, as DA syndromes because their clinical features over-
lap those of DA type 1 (DA1A [MIM: 108120] and DA1B
[MIM: 614335]) and Freeman-Sheldon syndrome, or
DA2A (MIM: 193700). Autosomal-dominant MPS, or DA8
(MIM: 178110), is one of the conditions that was added
to the DA classification on the basis of the phenotypic fea-
tures of four reported families in whom pterygia, campto-
dactyly of the hands, vertebral fusions, and scoliosis were
transmitted from parent to child.2–5
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The Amtics consistent with the diagnosis of DA8 and evidence of
parent-to-child transmission were referred to our research
program on DA syndromes (Table 1; Figures 1 and 2;
Figure S1). To identify the gene(s) harboring mutations
underlying DA8, we initially used Sanger sequencing to
screen the proband of each family for mutations in
genes known to contain mutations underlying lethal
MPS (MIM: 253290) and non-lethal Escobar-variant auto-
somal-recessive MPS (MIM: 265000); these genes include
CHRNG7,8 (MIM: 100730), CHRND9 (MIM: 100720), and
CHRNA19 (MIM: 100690), as well as IRF610 (MIM:
607199), mutations in which cause popliteal pterygium
syndrome (MIM: 119500). No pathogenic mutations
were found in any of these candidate genes. Next, we per-
formed exome sequencing on seven individuals in family
A, three individuals in family B, and two affected individ-
uals (III-5 and V-2) in family C (Table 1; Figures 1 and 2;
Figure S1). All studies were approved by the institutional
review boards of the University of Washington and Seattle
Children’s Hospital, and informed consent was obtained
from each participant.
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Table 1. Mutations in and Clinical Findings for Individuals with DA8
Family A Family B Family C Family D
III-1 III-2 II-2 III-2 II-1 III-5a IV-3 V-2 II-1 I-1
Mutation Information
MYH3 exon 25 25 25 25 25 8 8 8 no mutation
identified
no mutation
identified
cDNA change c.3214_3216dup c.3214_3216dup c.3214_3216dup c.3224A>C c.3224A>C c.727_729del c.727_729del c.727_729del NA NA
Predicted protein
alteration
p.Asn1072dup p.Asn1072dup p.Asn1072dup p.Gln1075Pro p.Gln1075Pro p.Ser243del p.Ser243del p.Ser243del NA NA
GERP score 5.64 5.64 5.64 5.64 5.64 4.94 4.94 4.94 NA NA
CADD score v.1.1
(phred-like)
17.62 17.62 17.62 20.8 20.8 18.47 18.47 18.47 NA NA
PolyPhen-2 score
(HumVar)
NA NA NA 0.931 0.931 NA NA NA NA NA
Clinical Features: Face
Downslanting
palpebral fissures
þ þ þ þ þ ND   þ þ
Ptosis  þ  þ þ ND   þ þ
Long nasal bridge þ þ þ þ þ ND   þ þ
Low-set,
posteriorly
rotated ears
   þ þ ND þ þ þ þ
Clinical Features: Limbs
Hypoplastic
flexion creases
þ þ þ þ þ ND þ þ þ þ
Camptodactyly þ þ þ þ þ ND þ þ þ þ
Antecubital
webbing
    þ ND  þ  
Elbow
contractures
þ þ þ þ þ ND  þ  
Limited forearm
supination
þ þ þ ND þ ND ND ND þ þ
Hip contractures ND ND ND ND þ ND  ND þ 
Knee contractures  þ þ þ þ þ þ þ  
Popliteal webbing  þ þ ND þ ND þ þ  
(Continued on next page)
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The Am(NEBNext End Repair Module), A-tailing (NEBNext dA-
Tailing Module), and PCR amplification with ligation of
8-bp barcoded sequencing adaptors (Enzymatics Ultrapure
T4 Ligase) for multiplexing. 1 mg of barcoded shotgun li-
brary was hybridized to the capture probes targeting
~36.5 Mb of coding exons (Roche Nimblegen SeqCap EZ
Human Exome Library v.2.0). Library quality was deter-
mined by examination of molecular-weight distribution
and sample concentration (Agilent Bioanalyzer). Pooled,
barcoded libraries were sequenced via paired-end 50-bp
reads and an 8-bp barcode read on Illumina HiSeq
sequencers.
Demultiplexed BAM files were aligned to a human refer-
ence sequence (UCSC Genome Browser hg19) via the Bur-
rows-Wheeler Aligner v.0.6.2. Read data from a flow-cell
lane were treated independently for alignment and
quality-control purposes in instances where the merging
of data from multiple lanes was required. All aligned read
data were subjected to (1) removal of duplicate reads
(Picard MarkDuplicates v.1.70), (2) indel realignment
(Genome Analysis Toolkit [GATK] IndelRealigner v.1.6-
11-g3b2fab9), and (3) base-quality recalibration (GATK
TableRecalibration v.1.6-11-g3b2fab9). Single-nucleotide
variant (SNV) detection and genotyping were performed
with the GATK UnifiedGenotyper (v.1.6-11-g3b2fab9).
SNV data for each sample were formatted (variant-call
format [VCF]) as ‘‘raw’’ calls that contained individual ge-
notype data for one or multiple samples and flagged with
the filtration walker (GATK) for marking sites that were po-
tential false positives or of lower quality (e.g., strand bias
[SB R 0.1], low quality scores [QUAL % 50], allelic imbal-
ance [ABHet > 0.75], long homopolymer runs [HRun >
4], and/or low quality by depth [QD < 5]).
Because DA8 is extremely rare (only four affected fam-
ilies have been reported to date2–5), we excluded SNVs
with an alternative allele frequency > 0.0001 in any popu-
lation in the NHLBI Exome Sequencing Project Exome
Variant Server dataset ESP6500, 1000 Genomes, the Exome
Aggregation Consortium (ExAC v.1.0) Browser, or an inter-
nal database of ~700 exomes. Additionally, SNVs that were
flagged as low quality or potential false positives (QUAL%
50, HRun > 4, QD < 5, presence within a cluster of SNPs)
were also excluded from analysis.We generated copy-num-
ber variant (CNV) calls from exome data by using
CoNIFER.11 Variants were annotated with the SeattleSe-
qAnnotation 138 server, and SNVs for which the only
functional prediction label was ‘‘intergenic,’’ ‘‘coding-syn-
onymous,’’ ‘‘utr,’’ ‘‘near-gene,’’ or ‘‘intron’’ were excluded.
Individual genotypes with a depth < 6 or genotype quality
< 20 were treated as missing in the analysis.
To exclude known causes of MPS and well-known condi-
tions that include pterygia, we first assessed the exome
data for pathogenic variants in the genes previously
screened by Sanger sequencing (IRF6, CHRNG, CHRNA1,
and CHRND), as well as in RAPSN9,12 (MIM: 601592) and
DOK713 (MIM: 610285). No SNVs or CNVs in these genes
segregated with DA8 in any of the three families tested.erican Journal of Human Genetics 96, 841–849, May 7, 2015 843
AIII-2 AIII-1 AII-2
BII-2 BI-1
Figure 1. Phenotypic Characteristics of Individuals with DA8
Five individuals affected by DA8; all individuals shown haveMYH3mutations. Note the downslanting palpebral fissures, ptosis, camp-
todactyly of the fingers, scoliosis, short stature, and neck webbing. ID numbers for the individuals shown in this figure correspond to
those in Table 1, where there is a detailed description of the phenotype of each affected individual. Figure S1 provides a pedigree of
each DA8-affected family.Next, we looked for novel and/or rare SNVs and CNVs in
the same gene shared among affected probands. No genes
with rare or novel variants were shared among all three
families. Affected individuals in families A and B were
also screened for larger CNVs via array comparative
genomic hybridization on the Illumina Infinium Human-
Core-24 BeadChip. No shared or overlapping CNVs were
identified. Subsequently, we loosened our filtering criteria
to include variants in genes that were shared by two out
of three families and identified three candidate genes
(SHPRH [MIM: 608048], SLC5A9, and MYH3 [MIM:
160720]) in families A and B.
The known functions of SHPRH and SLC5A9 appeared to
be unrelated to the musculoskeletal phenotypes observed
in all three families: SHPRH is involved in DNA repair
and maintenance of genomic stability, and SLC5A9 en-
codes a sugar transporter primarily expressed in the small
intestine and kidneys. In contrast, mutations in MYH3
frequently cause other forms of distal arthrogryposis, spe-
cifically DA2A and DA2B14 (MIM: 601680) and, more
rarely, DA1.15,16 In addition to having congenital con-
tractures, persons with DA2A and DA2B variably have
short stature, scoliosis, and infrequently, pterygia of the
neck.17 Accordingly, we considered MYH3 to be the most
compelling candidate gene in these families.
In MYH3 (GenBank: NM_002470.3), we specifically
discovered variants c.3214_3216dup (p.Asn1072dup) in
family A and c.3224A>C (p.Gln1075Pro) in family B.
Both variants were subsequently validated via Sanger
sequencing and found to segregate with only the affected844 The American Journal of Human Genetics 96, 841–849, May 7, 2persons in each family (Figure 2). Both variants affect high-
ly conserved amino acid residues, have identical genomic
evolutionary rate profiling (GERP) scores of 5.64, and are
predicted to be deleterious by multiple methods (e.g.,
p.Asn1072dup has a combined annotation-dependent
depletion [CADD]18 score of 17.62, and p.Gln1075Pro
has a CADD score of 20.8). Moreover, neither variant was
found in more than 71,000 total control exomes recorded
in ESP6500, 1000 Genomes phase 1 (November 2010
release), internal databases (>1,400 chromosomes), and
the ExAC Browser (October 20, 2014, release).
Independently of the effort at the University of
Washington to identify a gene associated with DA8, inves-
tigators at Baylor College of Medicine identified a five-gen-
eration family in whom ten persons were reported to be
variably affected by a dominantly inherited condition
characterized by short stature, scoliosis, multiple vertebral
fusions, camptodactyly of the fingers, and multiple pte-
rygia (Table 1; Figure S1), consistent with the diagnosis of
DA8. Four individuals from this family were enrolled in a
research protocol approved by the institutional review
board at Baylor College of Medicine. Informed consent
was obtained from each of these individuals prior to enroll-
ment and prior to initiation of research studies. VCRome
v.2.1 target-capture reagents (Roche Nimblegen) were
used for performing whole-exome sequencing of DNA ob-
tained from peripheral-blood monocytes from the pro-
band (individual IV-3, Figure S1) and her father (individual
III-5, Figure S1). 19 Sequencing was conducted on the Illu-
mina HiSeq 2000 as previously described.19 Alignment,015
Figure 2. Radiograph of Severe Scoliosis and Vertebral Fusion
Observed in a Person with DA8
Severe, convex rightward, rotatory scoliosis of the thoracic and
lumbar spine in individual AIII-2 (Table 1 and Figure 1). Fusion
of vertebral bodies from T10 to L3 is indicated by the arrow.variant calling, and annotation were completed with the
Mercury pipeline.20 Comparison of exome sequence data
from the proband and her affected father (Table 1;
Figure S1) identified 46 shared rare variants (i.e., frequency
< 0.0001 in ESP6500, 1000 Genomes phase 1 [November
2010 release], and the ExAC Browser [October 20, 2014,
release]). No variants were identified in SHPRH or
SLC5A9; however, one MYH3 variant not found in any
other databases, c.727_729del (p.Ser243del), was found
to affect a highly conserved amino acid residue (GERP
score of 4.94) and was predicted to be highly deleterious
(CADD v.1.1 score of 18.47). This variant was validated
by Sanger sequencing and segregated in all of the affected
individuals for whom DNA was available for testing. This
variant was not observed in ESP6500, the ExAC Browser
(v.0.3, January 13, 2015, release), or 1000 Genomes
(October 2014 release).
In 2006, we reported that mutations in MYH3 cause
DA2A and DA2B.14 Nevertheless, MYH3 was never consid-
ered a high-priority candidate gene in individuals with
DA8 because affected individuals had multiple pterygia
of the limbs, severe scoliosis, and vertebral fusions and
did not have contractures of the facial muscles. More
recently, we and others identified mutations in MYH3 in
DA1-affected persons who had no facial contractures15,16
and DA2B-affected persons who had vertebral fusionsThe Amand severe congenital scoliosis,21 indicating that the
phenotypic spectrum associated with MYH3 variants is
broader than originally considered. This inference is now
supported by our observation that variants inMYH3 cause
DA8 and a wide range of phenotypic connective-tissue ab-
normalities, including congenital contractures, multiple
pterygia, and bony fusions.
MYH3 encodes muscle embryonic myosin heavy chain
(MYH3), a skeletal-muscle myosin composed of a globular
motor domain (amino acid residues ~1–779) attached by
short neck (~779–840) and hinge (~840) regions to a
long coiled-coil rod domain (~840–1,940). The majority
of the rod region comprises themyosin tail domain (amino
acid residues ~1,070–1,940). Embryonic myosin exists as a
dimer in which the tail domains are intertwined (Figure 3).
Hundreds of myosin dimers assemble with one another
and other proteins to form the thick filaments of the sarco-
mere, which is the subcellular contractile apparatus of car-
diac-muscle and skeletal-muscle cells.
All of the mutations known to cause DA1, DA2A, and
DA2B16 affect amino acid residues in the head and neck
domains of embryonic myosin, whereas two of the three
mutations that cause DA8 affect the tail domain. The clin-
ical characteristics of the DA8-affected individuals with a
mutation affecting the tail domain were more alike than
the features of DA8-affected persons with a mutation
affecting the head domain. This observation is limited,
of course, by the fact that our dataset contained a
small number of both families and individuals with
DA8 caused by MYH3 mutations. Nevertheless, specula-
tion on domain-specific, or at least domain-predominant,
phenotypes has been reported previously for mutations in
both muscle and non-muscle myosins. For example, mu-
tations affecting the head domain of MYH9 (encoded by
MYH9 [MIM: 160775]) cause severe thrombocytopenia
and are associated with nephritis and deafness, whereas
mutations affecting the tail domain cause less severe
thrombocytopenia, such that median platelet counts
are more than two times higher than those associated
with head-domain mutations.22 Similarly, mutations
throughoutMYH7 (MIM: 160760) can cause hypertrophic
(MIM: 192600) and/or dilated cardiomyopathy (MIM:
613426), whereas skeletal myopathies (e.g., myosin-stor-
age myopathy [MIM: 608358] and Laing distal myopathy
[MIM: 160500]) are caused almost exclusively by muta-
tions affecting the tail domain of MYH7.23 Moreover,
mutations affecting the tail of MYH7 disrupt stability or
self-assembly of sarcomere filaments or protein-protein
interactions mediated through the tail, whereas muta-
tions affecting the motor appear to alter the ATPase and
actin-binding properties of myosin.24 This precedent of
domain-specific phenotypic differences associated with
mutations in other myosin-encoding genes suggests that
similar genotype-phenotype relationships might exist in
MYH3.
Skeletal abnormalities have not commonly been
observed, or at least reported, in persons with DA1, DA2A,erican Journal of Human Genetics 96, 841–849, May 7, 2015 845
1 115432 109876 20-2218-1915-171413 323029 23-26 413533 3431 37-403627 2812
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Distal arthrogryposis type 1
Distal arthrogryposis type 2A
Distal arthrogryposis type 2B
Multiple pterygium syndrome
head
neck
Figure 3. Genomic Model of MYH3 and Stylized Structure of Embryonic Myosin Illustrate the Spectrum of Mutations that Cause DA
Syndromes
MYH3 is composed of 41 exons, 39 of which are protein coding (blue) and two of which are non-coding (orange).
(A) Lines with attached dots indicate the approximate locations of MYH3 mutations that cause DA1 (green), DA2A (purple), DA2B
(orange), and DA8 (red). The color of each dot reflects the diagnosis.
(B) Schematic of an embryonicmyosin dimer. The approximate locations ofMYH3mutations relative to each affected amino acid residue
in themyosin domain are indicated by colored circles. All mutations causing DA1, DA2A, and DA2B affect amino acid residues located in
themotor and neck of embryonicmyosin, whereas the twomutations causing DA8 are the onlymutations that alter amino acid residues
located in the tail. (Both variants in the tail of MYH3 [c.4934A>C (p.Asp1622Ala) and c.2979C>T (p.Ala1637Val)] and reported by Toy-
demir et al.14 are now thought to be polymorphisms on the basis of additional family information and frequencies in large databases of
control populations.)or DA2B and with mutations in MYH3. Yet, skeletal
defectswere found ineachof the threeDA8-affected families
carrying an MYH3 mutation in our study. The most
common defects observed were vertebral abnormalities,
including hemivertebrae and vertebral fusions of C1 and
C2 or vertebrae of the thoracolumbar spine (Figure 2). A
similar range of vertebral abnormalities, as well as both
carpal and tarsal fusions, has been reported previously2–5
in families affected by dominantly inherited MPS. In addi-
tion, two persons in family C had craniosynostosis. These
observations suggest that embryonic myosin plays a role
in skeletal development, which is perturbed by the MYH3
mutations that cause DA8. Such a role for embryonic
myosin would not be unprecedented given that other pro-
teins of the contractile apparatus of skeletal muscle, such
as that encoded by troponin I type 2 (skeletal, fast) (TNNI2
[MIM: 191043]), are present in osteoblasts and chondro-
cytes in long-bone growth plates and play a role in skeletal
development.25 Moreover, multiple myosins have been re-
ported to interact with Runx2 in rat osteoblasts, and osteo-
blast differentiation in vitro has been associated with the
expression of myosin.26
To investigate this possibility further, we used MYH3-
cDNA-specific primers that we had previously devel-846 The American Journal of Human Genetics 96, 841–849, May 7, 2oped27 to test for MYH3 expression in a variety of human
fetal tissues. As expected, MYH3 was expressed in the
thymus, placenta, heart, and liver (Figure 4A). However,
whereas MYH3 expression was not detectable in cartilage,
it was expressed in bone (Figure 4A). Next, to determine
the relative expression levels of MYH3, we conducted a
qPCR assay and confirmed MYH3 expression in bone at
levels comparable to those in several other tissues,
including the brain, with known MYH3 expression28
(Figure 4B). These preliminary findings suggest that the
bony fusions in individuals with DA8 result from disrup-
tion of an unappreciated role of embryonic myosin in
vertebral development, and perhaps in skeletal develop-
ment in general.
Five simplex MPS cases referred to our center included
clinical characteristics that overlapped with DA8 and in
several instances were indistinguishable from DA8. Exome
sequencing did not reveal MYH3 mutations in any of the
affected individuals, but three of their cases were explained
by mutations in CHRNG. Specifically, two persons were
compound heterozygous (c.[753_754delCT];[805þ1G>A],
p.[Val253Alafs*44];[?] and c.[459dupA];[1082dupC],
p.[Val265Serfs*24];[Leu362Alafs*36]) and one was homozy-
gous (c.459dupA [p.Val154Serfs*24]) for CHRNGmutations015
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Figure 4. Expression of MYH3 in Bone
and Cartilage
(A) RNA was isolated from a 17-week-old
fetus, and cDNA was generated according
to standard protocols.27 MYH3 primers
were predicted to yield 313-bp amplicons
from genomic DNA (control) and 206-bp
amplicons from cDNA. MYH3 cDNA
expression was detected in the bone,
thymus, placenta, heart, brain, and liver.
Expression was not detected in cartilage,
lungs, or kidneys.
(B) qPCRwas used for assessing the relative
expression levels of MYH3 cDNA in bone,
cartilage, brain, heart, liver, and lungs.
MYH3 cDNA expression was detected in
bone at a level similar to that observed in
the brain and heart and was barely detect-
able in the lungs and cartilage.(GenBank: NM_005199.4). Two of these mutations,
c.753_754delCTandc.459dupA,havebeen reported inmul-
tiple individuals with recessively inheritedMPS1,8 and have
been described as ‘‘recurrent.’’ Yet, both of these mutations
are in ESP6500 and the ExAC Browser at frequencies as
high as 0.002 (e.g., c.753_754delCT in European Americans
in ESP6500), suggesting that standing rather than de
novo variation contributes to the relatively high incidence
of MPS caused by mutations in CHRNG. Moreover,
c.459dupA occurs on an identical ~700-kb haplotype in
each of the apparently unrelated MPS-affected persons
whom we tested. Therefore, the c.459dupA mutation most
likely arose many generations ago, and previous attempts
to identify the shared haplotype failed because of its small
size.1
Our findings collectively suggest that features such as
scoliosis and pterygia observed in individuals with DA8
most likely have a different underlying molecular mecha-
nism(s) than that in recessive forms of MPS caused by
mutations in the genes CHRNG, CHRND, and CHRNA1,9
encoding subunits of the skeletal-muscle nicotinic acetyl-
choline receptor (AChR). AChR is required for normalmus-
cle development, and muscle biopsies from individuals
with recessive MPS have demonstrated abnormal distribu-
tion of AChR and acetylcholinesterase.29 Because AChR is
necessary for proper organization and establishment of the
neuromuscular junction,30 as well as muscle and synaptic
maturation,31 it has been suggested that many features of
recessive MPS, such as joint contractures and pterygia,
are ultimately caused by fetal akinesia7 as a result of
abnormal muscle and synaptic development. In contrast,
MYH3 mutations that cause DA2A and/or DA2B are
hypothesized to alter contractile function of skeletal myo-
fibers during development, resulting in congenital con-
tractures and altered movement in utero. Consistent
with this hypothesis, we have recently demonstrated
that the MYH3 variant c.2014C>T (p.Arg672Cys), the
most common cause of DA2A, causes reduced contractile
force and prolonged relaxation of human skeletal myofib-
ers.27 Together, these findings suggest that pterygia in per-The Amsons with DA8 develop differently than in persons with
autosomal-recessive MPS.
We failed to identify the cause of dominantly inherited
MPS in one family originally diagnosed with DA8 (family
D in Table 1 and Figure S1). In retrospect, the phenotype
in this family differs from that found in the other DA8-
affected families. Specifically, neither of the affected per-
sons in this family have popliteal or antecubital ptergyia,
and both persons lack vertebral fusions. Additionally,
each individual has a ventriculoseptal defect. Accordingly,
although the lack of an MYH3 mutation in this family
could be interpreted as evidence that DA8 is genetically
heterogeneous, the alternative is that the phenotype in
this family is distinctive enough to prompt delineation
of a separate Mendelian condition.
In summary, we used exome sequencing to discover that
mutations in MYH3 cause DA8. The phenotypic overlap
among persons with DA8, coupled with physical findings
distinct from other DA conditions caused by mutations
inMYH3, suggests that the developmental mechanism un-
derlying DA8 differs from that underlying other DA condi-
tions and/or that certain functions of embryonic myosin
might be perturbed by disruption of specific residues
and/or domains.Supplemental Data
Supplemental Data include one figure and can be found with this
article online at http://dx.doi.org/10.1016/j.ajhg.2015.04.004.Consortia
The members of the University of Washington Center for Mende-
lian Genomics are Michael J. Bamshad, Jay Shendure, Deborah A.
Nickerson, Gonc¸alo R. Abecasis, Peter Anderson, Elizabeth March-
ani Blue, Marcus Annable, Brian L. Browning, Kati J. Buckingham,
Christina Chen, Jennifer Chin, Jessica X. Chong, Gregory M.
Cooper, Colleen P. Davis, Christopher Frazar, Tanya M. Harrell,
Zongxiao He, Preti Jain, Gail P. Jarvik, Guillaume Jimenez, Eric Jo-
hanson, Goo Jun,Martin Kircher, TomKolar, Stephanie A. Krauter,
Niklas Krumm, Suzanne M. Leal, Daniel Luksic, Colby T. Marvin,erican Journal of Human Genetics 96, 841–849, May 7, 2015 847
Margaret J. McMillin, Sean McGee, Patrick O’Reilly, Bryan Paeper,
Karynne Patterson, Marcos Perez, Sam W. Phillips, Jessica Pijoan,
Christa Poel, Frederic Reinier, Peggy D. Robertson, Regie Santos-
Cortez, Tristan Shaffer, Cindy Shephard, Kathryn M. Shively,
Deborah L. Siegel, Joshua D. Smith, Jeffrey C. Staples, Holly K.
Tabor, Monica Tackett, Jason G. Underwood, Marc Wegener, Gao
Wang, Marsha M. Wheeler, and Qian Yi.Acknowledgments
We thank the families for their participation and support; Christa
Poel, Karynne Patterson, Jennifer Chin, Yuqing Chen, Alyssa Tran,
Philippe Campeau, and James Lu for technical assistance; and
Alice Ward Racca for helpful comments. Our work was supported
in part by grants from the NIH National HumanGenome Research
Institute and NHLBI (1U54HG006493 to M.B., D.N., and J.S.;
1RC2HG005608 to M.B., D.N., and J.S.; 5R000HG004316 to
H.K.T.), the Eunice Kennedy Shriver National Institute of Child
Health and Human Development (NICHD; 1R01HD048895 to
M.J.B.), the Life Sciences Discovery Fund (2065508 and
0905001), and the Washington Research Foundation. This work
was also supported by the Baylor College of Medicine Intellectual
and Developmental Disabilities Research Center (HD024064),
funded by the Eunice Kennedy Shriver NICHD (U54HG003273
and U54 U54HG006542 to R.A.G.; T32GM07526 to M.J. and
L.C.B.; P01HD070394 to B.L.). L.C.B. was also supported by the
Medical Genetics Training Award in Clinical Biochemical Genetics
fromGenzyme and the Annual Clinical GeneticsMeeting Founda-
tion for Genetic and Genomic Medicine, the National Urea Cycle
Disorders Foundation Fellowship, and a fellowship from the Urea
Cycle Disorders Consortium (U54HD061221), which is a part of
the NIH Rare Disease Clinical Research Network, supported
through collaboration among the Office of Rare Diseases Research,
the National Center for Advancing Translational Science, and the
Eunice Kennedy Shriver NICHD. D.K. was supported by the NIH
National Institute of Arthritis and Musculoskeletal and Skin Dis-
eases (R01AR066124).
Received: March 13, 2015
Accepted: April 7, 2015
Published: May 7, 2015Web Resources
The URLs for data presented herein are as follows:
ExAC Browser, http://exac.broadinstitute.org/
Human Genome Variation Society, http://www.hgvs.org/
mutnomen/
NHLBI Exome Sequencing Project (ESP) Exome Variant Server,
http://evs.gs.washington.edu/EVS/
OMIM, http://www.omim.org/
SeattleSeq Annotation 138, http://snp.gs.washington.edu/
SeattleSeqAnnotation138/
UCSC Genome Browser, http://genome.ucsc.eduReferences
1. Vogt, J., Morgan, N.V., Rehal, P., Faivre, L., Brueton, L.A.,
Becker, K., Fryns, J.P., Holder, S., Islam, L., Kivuva, E., et al.
(2012). CHRNG genotype-phenotype correlations in the mul-
tiple pterygium syndromes. J. Med. Genet. 49, 21–26.848 The American Journal of Human Genetics 96, 841–849, May 7, 22. Frias, J.L., Holahan, J.R., Rosenbloom, A.L., and Felman, A.H.
(1973). An autosomal dominant syndrome of multiple pteryg-
ium, ptosis, and skeletal abnormalities. Proceedings of the
Fourth International Conference on Birth Defects. Excerpta
Medica 19.
3. Kawira, E.L., and Bender, H.A. (1985). An unusual distal ar-
throgryposis. Am. J. Med. Genet. 20, 425–429.
4. McKeown, C.M., and Harris, R. (1988). An autosomal domi-
nant multiple pterygium syndrome. J. Med. Genet. 25, 96–
103.
5. Prontera, P., Sensi, A., Merlo, L., Garani, G., Cocchi, G., and
Calzolari, E. (2006). Familial occurrence of multiple pterygium
syndrome: expression in a heterozygote of the recessive form
or variability of the dominant form? Am. J. Med. Genet. A.
140, 2227–2230.
6. Bamshad, M., Jorde, L.B., and Carey, J.C. (1996). A revised and
extended classification of the distal arthrogryposes. Am. J.
Med. Genet. 65, 277–281.
7. Hoffmann, K., Mu¨ller, J.S., Stricker, S., Me´garbane´, A., Rajab,
A., Lindner, T.H., Cohen, M., Chouery, E., Adaimy, L., Gha-
nem, I., et al. (2006). Escobar syndrome is a prenatal myas-
thenia caused by disruption of the acetylcholine receptor fetal
g subunit. Am. J. Hum. Genet. 79, 303–312.
8. Morgan, N.V., Brueton, L.A., Cox, P., Greally, M.T., Tolmie, J.,
Pasha, S., Aligianis, I.A., van Bokhoven, H., Marton, T., Al-Gaz-
ali, L., et al. (2006). Mutations in the embryonal subunit of the
acetylcholine receptor (CHRNG) cause lethal and Escobar var-
iants of multiple pterygium syndrome. Am. J. Hum. Genet. 79,
390–395.
9. Michalk, A., Stricker, S., Becker, J., Rupps, R., Pantzar, T., Mier-
tus, J., Botta, G., Naretto, V.G., Janetzki, C., Yaqoob, N., et al.
(2008). Acetylcholine receptor pathway mutations explain
various fetal akinesia deformation sequence disorders. Am. J.
Hum. Genet. 82, 464–476.
10. Kondo, S., Schutte, B.C., Richardson, R.J., Bjork, B.C., Knight,
A.S., Watanabe, Y., Howard, E., de Lima, R.L.L.F., Daack-
Hirsch, S., Sander, A., et al. (2002). Mutations in IRF6 cause
Van der Woude and popliteal pterygium syndromes. Nat.
Genet. 32, 285–289.
11. Krumm, N., Sudmant, P.H., Ko, A., O’Roak, B.J., Malig, M.,
Coe, B.P., Quinlan, A.R., Nickerson, D.A., and Eichler, E.E.;
NHLBI Exome Sequencing Project (2012). Copy number vari-
ation detection and genotyping from exome sequence data.
Genome Res. 22, 1525–1532.
12. Vogt, J., Harrison, B.J., Spearman, H., Cossins, J., Vermeer, S.,
ten Cate, L.N., Morgan, N.V., Beeson, D., and Maher, E.R.
(2008). Mutation analysis of CHRNA1, CHRNB1, CHRND,
and RAPSN genes in multiple pterygium syndrome/fetal aki-
nesia patients. Am. J. Hum. Genet. 82, 222–227.
13. Vogt, J., Morgan, N.V., Marton, T., Maxwell, S., Harrison, B.J.,
Beeson, D., and Maher, E.R. (2009). Germline mutation in
DOK7 associated with fetal akinesia deformation sequence.
J. Med. Genet. 46, 338–340.
14. Toydemir, R.M., Rutherford, A., Whitby, F.G., Jorde, L.B.,
Carey, J.C., and Bamshad, M.J. (2006). Mutations in embry-
onic myosin heavy chain (MYH3) cause Freeman-Sheldon
syndrome and Sheldon-Hall syndrome. Nat. Genet. 38, 561–
565.
15. Alvarado, D.M., Buchan, J.G., Gurnett, C.A., and Dobbs, M.B.
(2011). Exome sequencing identifies an MYH3 mutation in a
family with distal arthrogryposis type 1. J. Bone Joint Surg.
Am. 93, 1045–1050.015
16. Beck, A.E., McMillin, M.J., Gildersleeve, H.I., Kezele, P.R.,
Shively, K.M., Carey, J.C., Regnier, M., and Bamshad, M.J.
(2013). Spectrumofmutations that cause distal arthrogryposis
types 1 and 2B. Am. J. Med. Genet. A. 161A, 550–555.
17. Stevenson, D.A., Carey, J.C., Palumbos, J., Rutherford, A., Dol-
court, J., and Bamshad, M.J. (2006). Clinical characteristics
and natural history of Freeman-Sheldon syndrome. Pediatrics
117, 754–762.
18. Kircher, M., Witten, D.M., Jain, P., O’Roak, B.J., Cooper, G.M.,
and Shendure, J. (2014). A general framework for estimating
the relative pathogenicity of human genetic variants. Nat.
Genet. 46, 310–315.
19. Lupski, J.R., Gonzaga-Jauregui, C., Yang, Y., Bainbridge, M.N.,
Jhangiani, S., Buhay, C.J., Kovar, C.L., Wang, M., Hawes, A.C.,
Reid, J.G., et al. (2013). Exome sequencing resolves
apparent incidental findings and reveals further complexity
of SH3TC2 variant alleles causing Charcot-Marie-Tooth neu-
ropathy. Genome Med. 5, 57.
20. Reid, J.G., Carroll, A., Veeraraghavan, N., Dahdouli, M., Sund-
quist, A., English, A., Bainbridge, M., White, S., Salerno, W.,
Buhay, C., et al. (2014). Launching genomics into the cloud:
deployment of Mercury, a next generation sequence analysis
pipeline. BMC Bioinformatics 15, 30.
21. Beck, A.E., McMillin, M.J., Gildersleeve, H.I., Shively, K.M.,
Tang, A., and Bamshad, M.J. (2014). Genotype-phenotype re-
lationships in Freeman-Sheldon syndrome. Am. J. Med.
Genet. A. 164A, 2808–2813.
22. Pecci, A., Panza, E., Pujol-Moix, N., Klersy, C., Di Bari, F., Bozzi,
V., Gresele, P., Lethagen, S., Fabris, F., Dufour, C., et al. (2008).
Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA)
mutations predicts the natural history of MYH9-related dis-
ease. Hum. Mutat. 29, 409–417.
23. Tajsharghi, H., and Oldfors, A. (2013). Myosinopathies: pa-
thology and mechanisms. Acta Neuropathol. 125, 3–18.
24. Armel, T.Z., and Leinwand, L.A. (2009). Mutations in the
beta-myosin rod cause myosin storage myopathy via mul-The Amtiple mechanisms. Proc. Natl. Acad. Sci. USA 106, 6291–
6296.
25. Zhu, X., Wang, F., Zhao, Y., Yang, P., Chen, J., Sun, H., Liu, L.,
Li, W., Pan, L., Guo, Y., et al. (2014). A gain-of-function
mutation in Tnni2 impeded bone development through
increasing Hif3a expression in DA2B mice. PLoS Genet. 10,
e1004589.
26. Zhang, J., Lazarenko, O.P., Blackburn, M.L., Shankar, K.,
Badger, T.M., Ronis, M.J.J., and Chen, J.-R. (2011). Feeding
blueberry diets in early life prevent senescence of osteoblasts
and bone loss in ovariectomized adult female rats. PLoS
ONE 6, e24486.
27. Racca, A.W., Beck, A.E., McMillin, M.J., Korte, F.S., Bamshad,
M.J., and Regnier, M. (2015). The embryonic myosin R672C
mutation that underlies Freeman-Sheldon syndrome impairs
cross-bridge detachment and cycling in adult skeletal muscle.
Hum. Mol. Genet. Published online March 3, 2015.
28. Chong, J.X., McMillin, M.J., Shively, K.M., Beck, A.E., Marvin,
C.T., Armenteros, J.R., Buckingham, K.J., Nkinsi, N.T., Boyle,
E.A., Berry, M.N., et al.; University of Washington Center for
Mendelian Genomics (2015). De Novo Mutations in NALCN
Cause a Syndrome Characterized by Congenital Contractures
of the Limbs and Face, Hypotonia, and Developmental Delay.
Am. J. Hum. Genet. 96, 462–473.
29. Robinson, K.G., Viereck, M.J., Margiotta, M.V., Gripp, K.W.,
Abdul-Rahman, O.A., and Akins, R.E. (2013). Neuromotor
synapses in Escobar syndrome. Am. J. Med. Genet. A. 161A,
3042–3048.
30. Koenen, M., Peter, C., Villarroel, A., Witzemann, V., and Sak-
mann, B. (2005). Acetylcholine receptor channel subtype di-
rects the innervation pattern of skeletal muscle. EMBO Rep.
6, 570–576.
31. Takahashi, M., Kubo, T., Mizoguchi, A., Carlson, C.G., Endo,
K., and Ohnishi, K. (2002). Spontaneous muscle action poten-
tials fail to develop without fetal-type acetylcholine receptors.
EMBO Rep. 3, 674–681.erican Journal of Human Genetics 96, 841–849, May 7, 2015 849
